NYSE:PHRHealthcare Services
Phreesia (PHR) Is Down 25.5% After Cutting 2027 Revenue Outlook Amid Pharma Spend Uncertainty – Has The Bull Case Changed?
In late March 2026, Phreesia, Inc. reported fourth-quarter and full-year results showing higher revenue and a swing to GAAP profitability, while also cutting its fiscal 2027 revenue outlook to US$510 million–US$520 million amid reduced visibility into pharmaceutical client spending.
The company simultaneously filed a US$34.61 million shelf registration for 3,033,251 common shares tied to an ESOP-related offering, highlighting ongoing use of equity-based compensation even as management guides...